Publications by authors named "Nuzhat Pathan"

Claim this Profile
A
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer.
Gregory J Riely, Egbert F Smit, Myung-Ju Ahn, Enriqueta Felip, Suresh S Ramalingam, Nuzhat Pathan

Future Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With -Mutant Metastatic Non-Small-Cell Lung Cancer.
Gregory J Riely, Egbert F Smit, Myung-Ju Ahn, Enriqueta Felip, Suresh S Ramalingam, Nuzhat Pathan

J Clin Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
Giuseppe Curigliano, Geoffrey I Shapiro, Rebecca S Kristeleit, Albiruni R Abdul Razak, Stephen Leong, Nuzhat Pathan

Br J Cancer· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
Giuseppe Curigliano, Geoffrey I Shapiro, Rebecca S Kristeleit, Albiruni R Abdul Razak, Stephen Leong, Nuzhat Pathan

Br J Cancer· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer.
Byoung Chul Cho, Sarah B Goldberg, Dong-Wan Kim, Mark A Socinski, Timothy F Burns, Nuzhat Pathan

Expert Opin Investig Drugs· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer.
Zev A Wainberg, Maria Alsina, Heloisa P Soares, Irene Braña, Carolyn D Britten, Nuzhat Pathan

Target Oncol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors.
Anthony W Tolcher, Mario Sznol, Siwen Hu-Lieskovan, Kyriakos P Papadopoulos, Amita Patnaik, Nuzhat Pathan

Clin Cancer Res· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a Novel Allosteric Inhibitory Site on Tryptophan Hydroxylase 1 Enabling Unprecedented Selectivity Over all Related Hydroxylases.
Mike Petrassi, Rob Barber, Celine Be, Sarah Beach, Brian Cox, Nuzhat Pathan

Front Pharmacol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peginterferon Beta-1a Shows Antitumor Activity as a Single Agent and Enhances Efficacy of Standard of Care Cancer Therapeutics in Human Melanoma, Breast, Renal, and Colon Xenograft Models.
Antonio Boccia, Cyrus Virata, Daniel Lindner, Nicki English, Nuzhat Pathan

J Interferon Cytokine Res· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor.
Yong Jia, Jose Juarez, Jie Li, Mari Manuia, Matthew J Niederst, Nuzhat Pathan

Cancer Res· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based design of 2,6,7-trisubstituted-7H-pyrrolo[2,3-d]pyrimidines as Aurora kinases inhibitors.
Jean-Yves Le Brazidec, Angela Pasis, Betty Tam, Christina Boykin, Deping Wang, Nuzhat Pathan

Bioorg Med Chem Lett· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis, SAR and biological evaluation of 1,6-disubstituted-1H-pyrazolo[3,4-d]pyrimidines as dual inhibitors of Aurora kinases and CDK1.
Jean-Yves Le Brazidec, Angela Pasis, Betty Tam, Christina Boykin, Cheryl Black, Nuzhat Pathan

Bioorg Med Chem Lett· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery.
Daniel A Erlanson, Joseph W Arndt, Mark T Cancilla, Kathy Cao, Robert A Elling, Nuzhat Pathan

Bioorg Med Chem Lett· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines.
Nuzhat I Pathan, Peter Chu, Kandasamy Hariharan, Carolyn Cheney, Arturo Molina

Blood· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis